
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Pediatr.
Sec. Neonatology
Volume 13 - 2025 | doi: 10.3389/fped.2025.1492716
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Caffeine is a proven medication used for the prevention and treatment of apnea in premature infants, offering both short- and long-term benefits. International guidelines provide a range of recommendations regarding the preterm population eligible for caffeine prophylaxis, including the timing, dosage, and duration of treatment. Our national guidelines, published prior to the most recent updates of the international guidelines, recommend the use of caffeine citrate starting from the first day after delivery for preterm infants with a gestational age of <28 weeks. For infants up to 32 weeks, if positive pressure ventilation is required, the decision should be made on an individual basis. This study aims to describe the variability in caffeine usage across neonatal intensive care units in our country.Methods: An online survey was sent to neonatologist who are members of the Turkish Neonatology Society to describe the variability in caffeine usage in neonatal intensive care units in our country. Results: We collected responses from 74 units. Prophylactic caffeine usage was observed as; GA < 276/7: 98.6%, GA 280/7-286/7: 89.0%, GA 290/7-296/7: 75.3%, GA 300/7-316/7: 53.4%. 62.2% of units reported administering loading dose within the first two hours. The initial maintenance dose was 5 mg/kg in 64.8% of units, 10 mg/kg in 32.4% of units, and intermediate dose in 5.3% of units. 47.3% of units reported no routine dose adjustment. The postmenstrual age that caffeine treatment was stopped was found to be 34 (min-max; 32-36) weeks for infants without apnea and respiratory support, 36 (min-max; 34-52) weeks for infants without apnea but any respiratory support. The time to discharge after treatment cessation was found as; 1-4 days: 37.8%, 5-7 days: 68.9%. Among the 56 units with multiple responsible physicians, 32.1% reported intra-unit variations. Conclusion: The significant differences in caffeine usage characteristics between and within units highlight the need for clear recommendations provided by standardized guidelines.
Keywords: Caffeine, Premature neonate, apnea of prematurity, neonatal intensive care unit, guideline
Received: 07 Sep 2024; Accepted: 28 Jan 2025.
Copyright: © 2025 Unal, Beken, Anuk Ince, Turan, Korkmaz, Ecevit, AKCAN, Akın, Aktaş, Aladağ Çiftdemir, Altuncu, Altunhan, Arcagök, Armangil, Özer, Aydın, Bezirganoglu, Bilgin, Calısıcı, Çalkavur, Celik, Celik, Cetinkaya, Cetinkaya, Demirel, Demirel, Dogan, Doğan, Durukan, Engür, Ercan, Gokmen, Guney Varal, Gulasi, Gunlemez, Gursoy, Toptan, Hamitoğlu, Isleyen, Iyigun, Kader, Kahvecioğlu, Kaykı, Kostu, Kurnaz, Mammadalıyev, MUNGAN AKIN, Narlı, Okulu, OKUR, Olukman, Ovalı, Ozcan, Ozdemir, Ozdemir, Özkan, Sandal, Sarici, Sivrikaya Yildirim, SİYAH BİLGİN, Uygun, Surmeli Onay, Simsek, Tandırcıoğlu, Tanriverdi, Tekgündüz, Terek, Tunc, Tunc, Tutak, Tufekcioğlu, Tuzun, Ulu, Ulubas Isik, Uras, Uslu, Unal and Hilal Yılmaz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Serdar Beken, Acıbadem University, Istanbul, Türkiye
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.